Analyst Activity – HC Wainwright Reiterates Buy on NASDAQ:BTAI – BioXcel Therapeutics (NASDAQ:BTAI)

Analyst Ratings For NASDAQ:BTAI – BioXcel Therapeutics (NASDAQ:BTAI)

Story continues below

Today, HC Wainwright reiterated its Buy rating on NASDAQ:BTAI – BioXcel Therapeutics (NASDAQ:BTAI) with a price target of $25.00.

Some recent analyst ratings include

  • 6/12/2018-HC Wainwright Reiterated Rating of Buy.
  • 4/2/2018-Canaccord Genuity initiated coverage with a Buy rating.
  • 4/2/2018-BMO Capital Markets initiated coverage with a Outperform rating.
  • 4/2/2018-UBS Group initiated coverage with a Buy rating.
  • 4/2/2018-Barclays initiated coverage with a Overweight ➝ Overweight rating.


    Recent Trading Activity for NASDAQ:BTAI – BioXcel Therapeutics (NASDAQ:BTAI)
    Shares of NASDAQ:BTAI – BioXcel Therapeutics closed the previous trading session at 10.34 down -0.39 3.59% with 10.3100004196167 shares trading hands.

    An ad to help with our costs